Amylin/Lilly’s Once-Weekly Exenatide Wins Head-To-Head Over Byetta
This article was originally published in The Pink Sheet Daily
Executive Summary
Firms expect to file NDA by end of first half 2009.
You may also be interested in...
Byetta Safety Concerns Could Set Roadblocks Ahead For New GLP-1s
Amylin/Lilly’s Byetta LAR and Novo Nordisk’s liraglutide could face tougher regulatory scrutiny after cases of pancreatitis are linked to exenatide.
Byetta Safety Concerns Could Set Roadblocks Ahead For New GLP-1s
Amylin/Lilly’s Byetta LAR and Novo Nordisk’s liraglutide could face tougher regulatory scrutiny after cases of pancreatitis are linked to exenatide.
Amylin Halts Development Of Symlin With Approved Appetite Suppressants
The 2009 filing timeline for once-weekly exenatide could be hastened if FDA does not require bioequivalence data, firm says.